Cardiome Pharma Corp., of Vancouver, British Columbia, priced its previously announced underwritten public offering of 10 million common shares at $3 per common share, for aggregate gross proceeds of $30 million. Read More
Viking Therapeutics Inc., of San Diego, reported top-line results from a proof-of-concept study in a mouse model of X-linked adrenoleukodystrophy (X-ALD), showing that VK0214 rapidly reduced plasma very long chain fatty acid (VLCFA) levels by more than 25 percent in treated animals compared with vehicle controls (p < 0.01). Read More
An expected increase in the number of generic drug applications submitted to the FDA is lowering the ANDA user fees for fiscal 2017, but that savings will be offset by higher facility fees. Read More
A major problem facing people sickened or threatened by neglected diseases is that the for-profit global biopharmaceutical industry sets the agenda for new drug development, and their suffering is not considered worth the investment. Read More
DUBLIN – Immunoqure AG is parlaying an extensive auto-antibody characterization effort involving a cohort of patients with an ultra-rare autoimmune disease into an antibody discovery engine that has uncovered large numbers of highly active antibodies with the potential to address a swath of immunological conditions. Read More
HONG KONG – A team of Chinese scientists from Sichuan University's West China Hospital in the city of Chengdu is one step closer to initiating the world's first human CRISPR clinical trial to test gene-editing technology in a lung cancer treatment. Read More
Comprehensive health assessment of a group of 13 cloned sheep, including the "Nottingham Dollies," four sheep that were created from the same cell line as Dolly the Sheep, has shown that, as a group, the animals were no more prone to health problems than naturally conceived sheep of the same age. Read More
As Celgene Corp. made ready to unveil second-quarter earnings Thursday, onlookers were disappointed but not hugely surprised by the firm's disclosure that it would not seek approval in diffuse large B-cell lymphoma (DLBCL) with Revlimid (lenalidomide), due to a miss on the key secondary endpoint of overall survival (OS) in interim results from a phase III trial called REMARC. Read More
Tokai Pharmaceuticals Inc. called off a pivotal phase III trial comparing its triple-acting prostate cancer drug, galeterone, to Xtandi (enzalutamide, Medivation Inc.) after a data monitoring committee determined the trial was unlikely to meet its primary endpoint. Read More
Disappointing second-quarter earnings at Gilead Sciences Inc. forced shares (NASDAQ:GILD) down 8.5 percent Tuesday, closing at $81.05 for a loss of $7.50, and led to a chorus of calls for the company to pull the trigger on a big deal. Read More
